Systemic mastocytosis

American Journal of the Medical Sciences

Volumn 342, Issue 5, 2011, Pages 409-415

  Ozdemir, Didem ^a   Dagdelen, Selcuk ^a   Erbas, Tomris ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Classification; D816V mutation; Imatinib mesylate; Systemic mastocytosis; Tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; CLADRIBINE; CORTICOSTEROID; DASATINIB; IMATINIB; MIDOSTAURIN; NILOTINIB; PREDNISONE; TRYPTASE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CELL INFILTRATION; CYTOPENIA; DEATH; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HEPATOMEGALY; HUMAN; HYPERHIDROSIS; HYPOTENSION; IMMUNOPHENOTYPING; LIFE EXPECTANCY; LYMPHADENOPATHY; MAST CELL DEGRANULATION; MAST CELL LEUKEMIA; MYELODYSPLASTIC SYNDROME; OPPORTUNISTIC INFECTION; OSTEOLYSIS; PROGNOSIS; REVIEW; SARCOMA; SIDE EFFECT; SPLENOMEGALY; SYMPTOMATOLOGY; SYNCOPE; SYSTEMIC MASTOCYTOSIS; TACHYCARDIA; TREATMENT RESPONSE; URTICARIA PIGMENTOSA;

EID: 80055052397     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3182121131     Document Type: Review

References (60)

1. Pardanani A, Kimlinger T, Reeder T, et al. Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients. Leuk Res 2004;28:777-83. (Pubitemid 38760039)
2. Rivera J, Gilfillan AM. Molecular regulation of mast cell activation. J Allergy Clin Immunol 2006;117:1214-25. (Pubitemid 43795719)
3. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114: 937-51.
4. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25:603-25. (Pubitemid 32506768)
5. Pardanani A, Tefferi A. Proposal for a revised classification of systemic mastocytosis. Blood 2010;115:2720-1.
6. Czarnetzki BM, Kolde G, Schoemann A, et al. Bone marrow findings in adult patients with urticaria pigmentosa. J Am Acad Dermatol 1988;18:45-51. (Pubitemid 18047864)
7. Hennessy B, Giles F, Cortes J, et al. Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience. Am J Hematol 2004;77:209-14. (Pubitemid 39430697)
8. González de Olano D, de la Hoz Caballer B, Núñez López R, et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy 2007;37:1547-55. (Pubitemid 47460231)
9. Brockow K, Jofer C, Behrendt H, et al. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008;63:226-32.
10. Barete S, Assous N, de Gennes C, et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 2010;69: 1838-41.
11. Johansson C, Roupe G, Lindstedt G, et al. Bone density, bone markers and bone radiological features in mastocytosis. Age Ageing 1996;25:1-7. (Pubitemid 26036220)
12. Khoury J, Jerushalmi J, Cohen HI, et al. Super scan leading to definitive diagnosis in a patient with recurrent syncope. Clin Nucl Med 2003;28:886-9. (Pubitemid 38281845)
13. van Daele PL, Beukenkamp BS, Geertsma-Kleinekoort WM, et al. Immunophenotyping of mast cells: a sensitive and specific diagnostic tool for systemic mastocytosis. Neth J Med 2009;67:142-6.
14. Núñez-López R, Escribano L, Schernthaner GH, et al. Overexpression of complement receptors and related antigens on the surface of bone marrow mast cells in patients with systemic mastocytosis. Br J Haematol 2003;120:257-65. (Pubitemid 36194174)
15. Schwartz LB. Tryptase: a clinical indicator of mast-cell dependent events. Allergy Proc 1994;15:119-23. (Pubitemid 24209809)
16. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009;113:5727-36.
17. Sperr WR, Stehberger B, Wimazal F, et al. Serum tryptase measurements in patients with myelodysplastic syndromes. Leuk Lymphoma 2002;43:1097-105. (Pubitemid 34464071)
18. Samorapoompichit P, Kiener HP, Schernthaner GH, et al. Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms. Blood 2001; 98:2580-3.
19. Proelss J, Wenzel J, Ko Y, et al. Tryptase detection in bone-marrow blood: a new diagnostic tool in systemic mastocytosis. J Am Acad Dermatol 2007;56:453-7. (Pubitemid 46273841)
20. Austen KF, Boyce JA. Mast cell lineage development and phenotypic regulation. Leuk Res 2001;25:511-8. (Pubitemid 32506757)
21. Tan A, Westerman D, McArthur GA, et al. Sensitive detection of KIT D816V in patients with mastocytosis. Clin Chem 2006;52:2250-7. (Pubitemid 44924999)
22. Horny HP, Sotlar K, Sperr WR, et al. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 2004;57:604-8. (Pubitemid 38725760)
23. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006;108:2366-72. (Pubitemid 44497521)
24. Bü ttner C, Henz BM, Welker P, et al. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J Invest Dermatol 1998;111:1227-31. (Pubitemid 29115205)
25. Pullarkat VA, Pullarkat ST, Calverley DC, et al. Mast cell disease associated with acute myeloid leukemia: detection of a new c-kit mutation Asp816His. Am J Hematol 2000;65:307-9.
26. Yavuz AS, Lipsky PE, Yavuz S, et al. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 2002;100: 661-5. (Pubitemid 34761133)
27. Akin C, Kirshenbaum AS, Semere T, et al. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol 2000;28:140-7. (Pubitemid 30100820)
28. Swolin B, Rödjer S, Roupe G. Cytogenetic studies in patients with mastocytosis. Cancer Genet Cytogenet 2000;120:131-5. (Pubitemid 30609691)
29. Lishner M, Confino-Cohen R, Mekori YA, et al. Trisomies 9 and 8 detected by fluorescence in situ hybridization in patients with systemic mastocytosis. J Allergy Clin Immunol 1996;98:199-204. (Pubitemid 26289403)
30. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-14. (Pubitemid 36359296)
31. Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol 2010;126:1099-104.e4.
32. Travis WD, Li CY, Yam LT, et al. Significance of systemic mast cell disease with associated hematologic disorders. Cancer 1988;62:965-72.
33. Travis WD, Li CY, Hoagland HC, et al. Mast cell leukemia: report of a case and review of the literature. Mayo Clin Proc 1986;61:957-66. (Pubitemid 17205206)
34. Kojima M, Nakamura S, Itoh H, et al. Mast cell sarcoma with tissue eosinophilia arising in the ascending colon. Mod Pathol 1999;12:739-43. (Pubitemid 29354889)
35. Godt O, Proksch E, Streit V, et al. Short-and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis. Dermatology 1997;195:35-9. (Pubitemid 27326706)
36. Lavker RM, Schechter NM, Guzzo C, et al. Aggressive topical corticosteroid therapy: a novel approach to mast-cell-dependent cutaneous disorders. Dermatologica 1987;175:213-6. (Pubitemid 17146568)
37. Worobec AS, Kirshenbaum AS, Schwartz LB, et al. Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leuk Lymphoma 1996;22:501-8. (Pubitemid 26341017)
38. Yoshida C, Takeuchi M, Tsuchiyama J, et al. Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha. Intern Med 2009;48:1973-8.
39. Casassus P, Caillat-Vigneron N, Martin A, et al. Treatment of adult systemic mastocytosis with interferon-alfa: results of a multicentre phase II trial on 20 patients. Br J Haematol 2002;119:1090-7. (Pubitemid 35463838)
40. Irani AA, Nilsson G, Ashman LK, et al. Dexamethasone inhibits the development of mast cells from dispersed human fetal liver cells cultured in the presence of recombinant human stem cell factor. Immunology 1995;84:72-8.
41. Finotto S, Mekori YA, Metcalfe DD. Glucocorticoids decrease tissue mast cell number by reducing the production of the c-kit ligand, stem cell factor, by resident cells: in vitro and in vivo evidence in murine systems. J Clin Invest 1997;99:1721-8. (Pubitemid 27163824)
42. Delaporte E, Pierard E, Wolthers BG, et al. Interferon-alfa in combination with corticosteroids improves systemic mast cell disease. Br J Dermatol 1995;132:479-82.
43. Pardanani A, Tefferi A. Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Curr Opin Hematol 2010;17:125-32.
44. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, et al. Cladribine therapy for systemic mastocytosis. Blood 2003;102:4270-6. (Pubitemid 37494083)
45. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
46. Frost MJ, Ferrao PT, Hughes TP, et al. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 2002;1:1115-24.
47. Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet 2003;362:535-6.
48. Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, et al. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer 2006;107:345-51. (Pubitemid 44036564)
49. Tefferi A, Pardanani A. Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol 2004;11:58-64. (Pubitemid 38021722)
50. Verstovsek S, Akin C, Manshouri T, et al. Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit. Leuk Res 2006;30:1365-70. (Pubitemid 44307328)
51. Shah NP, Lee FY, Luo R, et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006;108:286-91. (Pubitemid 43990640)
52. Aichberger KJ, Sperr WR, Gleixner KV, et al. Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. Eur J Clin Invest 2008;38:869-73.
53. Gleixner KV, Mayerhofer M, Sonneck K, et al. Synergistic growthinhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica 2007;92:1451-9. (Pubitemid 350144119)
54. Ustun C, Corless CL, Savage N, et al. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. Leuk Res 2009;33:735-41.
55. Verstovsek S, Tefferi A, Cortes J, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008;14:3906-15.
56. Gleixner KV, Mayerhofer M, Aichberger KJ, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816Vmutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006;107:752-9. (Pubitemid 43076402)
57. Gotlib J, Berubé C, Growney JD, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005;106:2865-70. (Pubitemid 41510766)
58. Nakamura R, Chakrabarti S, Akin C, et al. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant 2006;37: 353-8. (Pubitemid 43250468)
59. Escribano L, Alvarez-Twose I, Sánchez-Muñoz L, et al. Prognosis in adultolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009;124:514-21.
60. Worobec AS. Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am 2000;14:659-87. (Pubitemid 30436939)